Veranderingen
On 14 juni 2026, 09:27:46 UTC,
-
No fields were updated. See the metadata diff for more details.
| f | 1 | { | f | 1 | { |
| 2 | "author": "USP Grade Ketamine", | 2 | "author": "USP Grade Ketamine", | ||
| 3 | "author_email": "inquiries.lyfeunit@proton.me", | 3 | "author_email": "inquiries.lyfeunit@proton.me", | ||
| 4 | "creator_user_id": "5ecc116b-5ec4-48f4-8366-afe5052790b1", | 4 | "creator_user_id": "5ecc116b-5ec4-48f4-8366-afe5052790b1", | ||
| 5 | "extras": [], | 5 | "extras": [], | ||
| 6 | "groups": [], | 6 | "groups": [], | ||
| 7 | "id": "0f014adc-ba39-47e5-b99e-3364976dae22", | 7 | "id": "0f014adc-ba39-47e5-b99e-3364976dae22", | ||
| 8 | "isopen": true, | 8 | "isopen": true, | ||
| 9 | "license_id": "other-at", | 9 | "license_id": "other-at", | ||
| 10 | "license_title": "Annan (Attribution)", | 10 | "license_title": "Annan (Attribution)", | ||
| 11 | "maintainer": "", | 11 | "maintainer": "", | ||
| 12 | "maintainer_email": "", | 12 | "maintainer_email": "", | ||
| 13 | "metadata_created": "2026-06-14T09:26:48.298300", | 13 | "metadata_created": "2026-06-14T09:26:48.298300", | ||
| n | 14 | "metadata_modified": "2026-06-14T09:27:46.536164", | n | 14 | "metadata_modified": "2026-06-14T09:27:46.703238", |
| 15 | "name": "usp-grade-ketamine-hcl-chemical-specification-guide", | 15 | "name": "usp-grade-ketamine-hcl-chemical-specification-guide", | ||
| 16 | "notes": "## 1. Abstract and Dataset Parameters\r\n\r\nThis dataset | 16 | "notes": "## 1. Abstract and Dataset Parameters\r\n\r\nThis dataset | ||
| 17 | documentation functions as an open-access industrial and | 17 | documentation functions as an open-access industrial and | ||
| 18 | pharmaceutical reference index establishing the structural chemistry, | 18 | pharmaceutical reference index establishing the structural chemistry, | ||
| 19 | raw material criteria, validation standards, and handling parameters | 19 | raw material criteria, validation standards, and handling parameters | ||
| 20 | for United States Pharmacopeia (USP) grade Ketamine Hydrochloride | 20 | for United States Pharmacopeia (USP) grade Ketamine Hydrochloride | ||
| 21 | ($C_{13}H_{16}ClNO \\cdot HCl$) bulk crystalline active pharmaceutical | 21 | ($C_{13}H_{16}ClNO \\cdot HCl$) bulk crystalline active pharmaceutical | ||
| 22 | ingredient (API). To ensure public safety, batch uniformity, and | 22 | ingredient (API). To ensure public safety, batch uniformity, and | ||
| 23 | therapeutic efficacy across downstream commercial processing, medical | 23 | therapeutic efficacy across downstream commercial processing, medical | ||
| 24 | compounding, and clinical development, bulk chemical agents must | 24 | compounding, and clinical development, bulk chemical agents must | ||
| 25 | adhere to strict, unyielding quality assurance | 25 | adhere to strict, unyielding quality assurance | ||
| 26 | methodologies.\r\n\r\nThis dataset bridges structural organic | 26 | methodologies.\r\n\r\nThis dataset bridges structural organic | ||
| 27 | chemistry specifications with strict national regulatory thresholds, | 27 | chemistry specifications with strict national regulatory thresholds, | ||
| 28 | tracking the molecular profile and identity testing requirements that | 28 | tracking the molecular profile and identity testing requirements that | ||
| 29 | govern high-purity crystalline lots. The technical data points, | 29 | govern high-purity crystalline lots. The technical data points, | ||
| 30 | stability criteria, and analytical thresholds logged across this | 30 | stability criteria, and analytical thresholds logged across this | ||
| 31 | profile are cross-referenced directly from the processing registries | 31 | profile are cross-referenced directly from the processing registries | ||
| 32 | hosted within the [Lyfeunit Ketamine Hydrochloride Reference | 32 | hosted within the [Lyfeunit Ketamine Hydrochloride Reference | ||
| 33 | nit.com/usp-grade-ketamine-hydrochloride-guide/).\r\n\r\n---\r\n\r\n## | 33 | nit.com/usp-grade-ketamine-hydrochloride-guide/).\r\n\r\n---\r\n\r\n## | ||
| 34 | 2. Structural Chemistry and Molecular Architecture\r\n\r\nKetamine | 34 | 2. Structural Chemistry and Molecular Architecture\r\n\r\nKetamine | ||
| 35 | Hydrochloride is an arylcyclohexylamine derivative structurally | 35 | Hydrochloride is an arylcyclohexylamine derivative structurally | ||
| 36 | recognized as a chiral compound containing a single asymmetric carbon | 36 | recognized as a chiral compound containing a single asymmetric carbon | ||
| 37 | center. It is synthetically generated and most frequently distributed | 37 | center. It is synthetically generated and most frequently distributed | ||
| 38 | as a racemic mixture consisting of equal proportions of two distinct | 38 | as a racemic mixture consisting of equal proportions of two distinct | ||
| 39 | enantiomeric configurations: $R$-(-)-ketamine and | 39 | enantiomeric configurations: $R$-(-)-ketamine and | ||
| 40 | $S$-(+)-ketamine.\r\n\r\n### 2.1 Molecular and Skeletal | 40 | $S$-(+)-ketamine.\r\n\r\n### 2.1 Molecular and Skeletal | ||
| 41 | Specifications\r\n\r\n* **Systematic Chemical Identifier:** | 41 | Specifications\r\n\r\n* **Systematic Chemical Identifier:** | ||
| 42 | 2-(2-Chlorophenyl)-2-(methylamino)cyclohexan-1-one hydrochloride\r\n* | 42 | 2-(2-Chlorophenyl)-2-(methylamino)cyclohexan-1-one hydrochloride\r\n* | ||
| 43 | **Empirical Formula Variant:** $C_{13}H_{16}ClNO \\cdot HCl$\r\n* | 43 | **Empirical Formula Variant:** $C_{13}H_{16}ClNO \\cdot HCl$\r\n* | ||
| 44 | **Exact Molecular Mass:** 274.19 grams per mole (g/mol)\r\n* | 44 | **Exact Molecular Mass:** 274.19 grams per mole (g/mol)\r\n* | ||
| 45 | **Physical Aggregation State:** Crystalline, granular white powder, | 45 | **Physical Aggregation State:** Crystalline, granular white powder, | ||
| 46 | completely odorless in its pure state\r\n* **Ionic Matrix:** | 46 | completely odorless in its pure state\r\n* **Ionic Matrix:** | ||
| 47 | Hydrochloric acid addition salt, which enhances crystalline stability | 47 | Hydrochloric acid addition salt, which enhances crystalline stability | ||
| 48 | and water-solubility matrices compared to its free-base | 48 | and water-solubility matrices compared to its free-base | ||
| 49 | state.\r\n\r\n### 2.2 Enantiomeric Variance Profiles\r\n\r\nWhile | 49 | state.\r\n\r\n### 2.2 Enantiomeric Variance Profiles\r\n\r\nWhile | ||
| 50 | standard bulk supplies exist as a racemic mixture, analytical data | 50 | standard bulk supplies exist as a racemic mixture, analytical data | ||
| 51 | registers must account for the distinct pharmacological properties of | 51 | registers must account for the distinct pharmacological properties of | ||
| 52 | each individual enantiomer:\r\n\r\n* **The S-(+) Enantiomer | 52 | each individual enantiomer:\r\n\r\n* **The S-(+) Enantiomer | ||
| 53 | (Esketamine):** Displays an NMDA receptor binding affinity | 53 | (Esketamine):** Displays an NMDA receptor binding affinity | ||
| 54 | approximately three to four times higher than the $R$-enantiomer, | 54 | approximately three to four times higher than the $R$-enantiomer, | ||
| 55 | providing potent anesthetic and analgesic responses at reduced target | 55 | providing potent anesthetic and analgesic responses at reduced target | ||
| 56 | dosages.\r\n* **The R-(-) Enantiomer (Arketamine):** Exhibits a lower | 56 | dosages.\r\n* **The R-(-) Enantiomer (Arketamine):** Exhibits a lower | ||
| 57 | direct affinity for the NMDA channel PCP binding site, yet is actively | 57 | direct affinity for the NMDA channel PCP binding site, yet is actively | ||
| 58 | researched for alternative downstream metabolic cascades that may | 58 | researched for alternative downstream metabolic cascades that may | ||
| 59 | induce prolonged neuroplastic modifications with minimal dissociative | 59 | induce prolonged neuroplastic modifications with minimal dissociative | ||
| 60 | side effects.\r\n\r\n---\r\n\r\n## 3. Strict Quality Control | 60 | side effects.\r\n\r\n---\r\n\r\n## 3. Strict Quality Control | ||
| 61 | Thresholds: USP Pharmacopeial Compliance\r\n\r\nFor a batch of raw | 61 | Thresholds: USP Pharmacopeial Compliance\r\n\r\nFor a batch of raw | ||
| 62 | crystalline powder to receive certified USP-grade clearance, it must | 62 | crystalline powder to receive certified USP-grade clearance, it must | ||
| 63 | undergo extensive analytical verification to confirm the absence of | 63 | undergo extensive analytical verification to confirm the absence of | ||
| 64 | dangerous synthesis byproducts, toxic heavy metals, and residual | 64 | dangerous synthesis byproducts, toxic heavy metals, and residual | ||
| 65 | chemical elements.\r\n\r\n### 3.1 Definitive Validation Requirements | 65 | chemical elements.\r\n\r\n### 3.1 Definitive Validation Requirements | ||
| 66 | Table\r\n\r\nThe following matrix delineates the mandatory | 66 | Table\r\n\r\nThe following matrix delineates the mandatory | ||
| 67 | quantitative standards and chemical verification thresholds required | 67 | quantitative standards and chemical verification thresholds required | ||
| 68 | for batch release approval:\r\n\r\n| Test Category | Compendial | 68 | for batch release approval:\r\n\r\n| Test Category | Compendial | ||
| 69 | Requirement Limit | Approved Analytic Instrumentation |\r\n| --- | --- | 69 | Requirement Limit | Approved Analytic Instrumentation |\r\n| --- | --- | ||
| 70 | | --- |\r\n| **Identification Assay (A)** | Infrared Absorption | 70 | | --- |\r\n| **Identification Assay (A)** | Infrared Absorption | ||
| 71 | Spectrum must match reference | Fourier-Transform Infrared (FTIR) | 71 | Spectrum must match reference | Fourier-Transform Infrared (FTIR) | ||
| 72 | |\r\n| **Identification Assay (B)** | Retention time must match | 72 | |\r\n| **Identification Assay (B)** | Retention time must match | ||
| 73 | reference standard | High-Performance Liquid Chromatography (HPLC) | 73 | reference standard | High-Performance Liquid Chromatography (HPLC) | ||
| 74 | |\r\n| **Assay Percentage** | 98.0% to 102.0% (Calculated on dried | 74 | |\r\n| **Assay Percentage** | 98.0% to 102.0% (Calculated on dried | ||
| 75 | basis) | Liquid Chromatography with UV Detection |\r\n| **pH | 75 | basis) | Liquid Chromatography with UV Detection |\r\n| **pH | ||
| 76 | Concentration Range** | 3.5 to 4.1 (In a 1-in-10 aqueous solution) | | 76 | Concentration Range** | 3.5 to 4.1 (In a 1-in-10 aqueous solution) | | ||
| 77 | Potentiometric Glass Electrode pH Meter |\r\n| **Residue on Ignition** | 77 | Potentiometric Glass Electrode pH Meter |\r\n| **Residue on Ignition** | ||
| 78 | | Not more than 0.1% cumulative ash | High-Temperature Muffle Furnace | 78 | | Not more than 0.1% cumulative ash | High-Temperature Muffle Furnace | ||
| 79 | |\r\n| **Loss on Drying** | Not more than 0.5% total volatile loss | | 79 | |\r\n| **Loss on Drying** | Not more than 0.5% total volatile loss | | ||
| 80 | Thermal Desiccation at 105\u00b0C |\r\n\r\n---\r\n\r\n## 4. | 80 | Thermal Desiccation at 105\u00b0C |\r\n\r\n---\r\n\r\n## 4. | ||
| 81 | Comprehensive Solubility Profiles and Vehicle | 81 | Comprehensive Solubility Profiles and Vehicle | ||
| 82 | Interactivity\r\n\r\nWhen formulating pure bulk Ketamine Hydrochloride | 82 | Interactivity\r\n\r\nWhen formulating pure bulk Ketamine Hydrochloride | ||
| 83 | powder into finished liquid parenterals, ophthalmic preparations, or | 83 | powder into finished liquid parenterals, ophthalmic preparations, or | ||
| 84 | topical transdermal delivery matrices, manufacturing engineers must | 84 | topical transdermal delivery matrices, manufacturing engineers must | ||
| 85 | carefully follow its specific solubility parameters to prevent | 85 | carefully follow its specific solubility parameters to prevent | ||
| 86 | spontaneous recrystallization.\r\n\r\n### 4.1 Quantitative Solubility | 86 | spontaneous recrystallization.\r\n\r\n### 4.1 Quantitative Solubility | ||
| 87 | Benchmarks\r\n\r\nKetamine Hydrochloride is highly hydrophilic due to | 87 | Benchmarks\r\n\r\nKetamine Hydrochloride is highly hydrophilic due to | ||
| 88 | its hydrochloride salt structure, allowing it to dissolve readily in | 88 | its hydrochloride salt structure, allowing it to dissolve readily in | ||
| 89 | polar solvent systems.\r\n\r\n* **Aqueous Media (Water):** Freely | 89 | polar solvent systems.\r\n\r\n* **Aqueous Media (Water):** Freely | ||
| 90 | soluble at an exact ratio of 1 gram of pure crystals per 4 milliliters | 90 | soluble at an exact ratio of 1 gram of pure crystals per 4 milliliters | ||
| 91 | of distilled water at an ambient temperature of 20\u00b0C.\r\n* | 91 | of distilled water at an ambient temperature of 20\u00b0C.\r\n* | ||
| 92 | **Dehydrated Alcohol (Ethanol):** Soluble at an exact ratio of 1 gram | 92 | **Dehydrated Alcohol (Ethanol):** Soluble at an exact ratio of 1 gram | ||
| 93 | per 14 milliliters of alcohol fluid.\r\n* **Organic Solvents | 93 | per 14 milliliters of alcohol fluid.\r\n* **Organic Solvents | ||
| 94 | (Chloroform):** Soluble; requires precise ventilation extraction | 94 | (Chloroform):** Soluble; requires precise ventilation extraction | ||
| 95 | controls due to solvent toxicity risks during processing.\r\n* | 95 | controls due to solvent toxicity risks during processing.\r\n* | ||
| 96 | **Non-Polar Fluids (Ether):** Practically insoluble; addition to ether | 96 | **Non-Polar Fluids (Ether):** Practically insoluble; addition to ether | ||
| 97 | systems triggers instant precipitation, dropping pure white crystals | 97 | systems triggers instant precipitation, dropping pure white crystals | ||
| 98 | out of the solution layer.\r\n\r\n### 4.2 Precipitation Prevention | 98 | out of the solution layer.\r\n\r\n### 4.2 Precipitation Prevention | ||
| 99 | Rules\r\n\r\nTo ensure compounded liquid solutions remain stable and | 99 | Rules\r\n\r\nTo ensure compounded liquid solutions remain stable and | ||
| 100 | uniform over time, automated formulation lines must maintain an acidic | 100 | uniform over time, automated formulation lines must maintain an acidic | ||
| 101 | pH buffer profile. If a solution containing dissolved ketamine ions is | 101 | pH buffer profile. If a solution containing dissolved ketamine ions is | ||
| 102 | introduced to an alkaline environment with a pH greater than 6.5, the | 102 | introduced to an alkaline environment with a pH greater than 6.5, the | ||
| 103 | hydrochloride bond is stripped away. This converts the molecule back | 103 | hydrochloride bond is stripped away. This converts the molecule back | ||
| 104 | into its hydrophobic free-base state, causing rapid precipitation and | 104 | into its hydrophobic free-base state, causing rapid precipitation and | ||
| 105 | clouding the liquid formulation.\r\n\r\n---\r\n\r\n## 5. Physical | 105 | clouding the liquid formulation.\r\n\r\n---\r\n\r\n## 5. Physical | ||
| 106 | Stability, Degradation Kinetics, and Storage Protocols\r\n\r\nPure | 106 | Stability, Degradation Kinetics, and Storage Protocols\r\n\r\nPure | ||
| 107 | USP-grade bulk active ingredients require strict environmental | 107 | USP-grade bulk active ingredients require strict environmental | ||
| 108 | controls during transport and storage to prevent chemical degradation | 108 | controls during transport and storage to prevent chemical degradation | ||
| 109 | or changes to the crystal lattice structure.\r\n\r\n### 5.1 | 109 | or changes to the crystal lattice structure.\r\n\r\n### 5.1 | ||
| 110 | Degradation Triggers and Reaction Vectors\r\n\r\nThough Ketamine | 110 | Degradation Triggers and Reaction Vectors\r\n\r\nThough Ketamine | ||
| 111 | Hydrochloride is relatively stable compared to more fragile biological | 111 | Hydrochloride is relatively stable compared to more fragile biological | ||
| 112 | molecules, it can degrade when exposed to prolonged environmental | 112 | molecules, it can degrade when exposed to prolonged environmental | ||
| 113 | stress:\r\n\r\n* **Thermal Stress:** High temperatures accelerate the | 113 | stress:\r\n\r\n* **Thermal Stress:** High temperatures accelerate the | ||
| 114 | formation of demethylated degradants, reducing the concentration of | 114 | formation of demethylated degradants, reducing the concentration of | ||
| 115 | the active compound.\r\n* **Photolytic Sensitivity:** Direct exposure | 115 | the active compound.\r\n* **Photolytic Sensitivity:** Direct exposure | ||
| 116 | to ultraviolet (UV) radiation breaks down the aromatic ring structure, | 116 | to ultraviolet (UV) radiation breaks down the aromatic ring structure, | ||
| 117 | causing the white powder to discolor into a yellowish tint and | 117 | causing the white powder to discolor into a yellowish tint and | ||
| 118 | producing trace amounts of compound anomalies.\r\n* **Hygroscopic | 118 | producing trace amounts of compound anomalies.\r\n* **Hygroscopic | ||
| 119 | Properties:** Exposure to ambient air with high relative humidity | 119 | Properties:** Exposure to ambient air with high relative humidity | ||
| 120 | causes the dry crystals to absorb moisture, leading to clumping, | 120 | causes the dry crystals to absorb moisture, leading to clumping, | ||
| 121 | inaccurate weight calculations, and potential hydrolysis over extended | 121 | inaccurate weight calculations, and potential hydrolysis over extended | ||
| 122 | storage periods.\r\n\r\n### 5.2 Controlled Storage | 122 | storage periods.\r\n\r\n### 5.2 Controlled Storage | ||
| 123 | Architecture\r\n\r\n```\r\n[Bulk Material Climate | 123 | Architecture\r\n\r\n```\r\n[Bulk Material Climate | ||
| 124 | Controls]\r\n\u251c\u2500\u2500 Temperature Tier: Maintained at a | 124 | Controls]\r\n\u251c\u2500\u2500 Temperature Tier: Maintained at a | ||
| 125 | strict 20\u00b0C to 25\u00b0C range (68\u00b0F to | 125 | strict 20\u00b0C to 25\u00b0C range (68\u00b0F to | ||
| 126 | 77\u00b0F)\r\n\u251c\u2500\u2500 Container Type: Heavy-duty amber | 126 | 77\u00b0F)\r\n\u251c\u2500\u2500 Container Type: Heavy-duty amber | ||
| 127 | glass or high-density polyethylene (HDPE) liners\r\n\u2514\u2500\u2500 | 127 | glass or high-density polyethylene (HDPE) liners\r\n\u2514\u2500\u2500 | ||
| 128 | Gas Environment: Sealed under a dry nitrogen blanket headspace to | 128 | Gas Environment: Sealed under a dry nitrogen blanket headspace to | ||
| 129 | eliminate ambient oxygen\r\n\r\n```\r\n\r\n---\r\n\r\n## 6. Global | 129 | eliminate ambient oxygen\r\n\r\n```\r\n\r\n---\r\n\r\n## 6. Global | ||
| 130 | Regulatory Controls and Distribution Tracking\r\n\r\nBecause Ketamine | 130 | Regulatory Controls and Distribution Tracking\r\n\r\nBecause Ketamine | ||
| 131 | Hydrochloride has a high potential for non-medical misuse, the | 131 | Hydrochloride has a high potential for non-medical misuse, the | ||
| 132 | international distribution of the raw USP-grade bulk material is | 132 | international distribution of the raw USP-grade bulk material is | ||
| 133 | subject to rigorous oversight by global law enforcement and health | 133 | subject to rigorous oversight by global law enforcement and health | ||
| 134 | agencies.\r\n\r\n### 6.1 Regulatory Oversight Classification\r\n\r\n* | 134 | agencies.\r\n\r\n### 6.1 Regulatory Oversight Classification\r\n\r\n* | ||
| 135 | **United States:** Categorized as a Schedule III Non-Narcotic | 135 | **United States:** Categorized as a Schedule III Non-Narcotic | ||
| 136 | Controlled Substance, subject to strict procurement quotas set by the | 136 | Controlled Substance, subject to strict procurement quotas set by the | ||
| 137 | Drug Enforcement Administration (DEA).\r\n* **International Level:** | 137 | Drug Enforcement Administration (DEA).\r\n* **International Level:** | ||
| 138 | Monitored under the United Nations Convention on Psychotropic | 138 | Monitored under the United Nations Convention on Psychotropic | ||
| 139 | Substances, requiring valid import, export, and transit permits for | 139 | Substances, requiring valid import, export, and transit permits for | ||
| 140 | all cross-border shipping.\r\n* **Industrial Auditing:** Facilities | 140 | all cross-border shipping.\r\n* **Industrial Auditing:** Facilities | ||
| 141 | processing raw bulk powders must undergo thorough physical | 141 | processing raw bulk powders must undergo thorough physical | ||
| 142 | inventories, maintain secure vault storage with biometric access, and | 142 | inventories, maintain secure vault storage with biometric access, and | ||
| 143 | keep real-time records of material balances down to the | 143 | keep real-time records of material balances down to the | ||
| 144 | milligram.\r\n\r\n### 6.2 Preventing Counterfeiting and | 144 | milligram.\r\n\r\n### 6.2 Preventing Counterfeiting and | ||
| 145 | Contamination\r\n\r\nTo ensure the integrity of the medical supply | 145 | Contamination\r\n\r\nTo ensure the integrity of the medical supply | ||
| 146 | chain, raw material shipments must be accompanied by a validated | 146 | chain, raw material shipments must be accompanied by a validated | ||
| 147 | Certificate of Analysis (CoA) that matches the batch's unique chemical | 147 | Certificate of Analysis (CoA) that matches the batch's unique chemical | ||
| 148 | fingerprint. Any discrepancy in melting point, colorimetric response, | 148 | fingerprint. Any discrepancy in melting point, colorimetric response, | ||
| 149 | or HPLC peak distribution requires the immediate quarantine of the | 149 | or HPLC peak distribution requires the immediate quarantine of the | ||
| 150 | entire lot to protect downstream clinical applications from potential | 150 | entire lot to protect downstream clinical applications from potential | ||
| 151 | counterfeit or contaminated materials.\r\n\r\n---\r\n\r\n## 7. | 151 | counterfeit or contaminated materials.\r\n\r\n---\r\n\r\n## 7. | ||
| 152 | Standardized Field Mapping for Institutional Registries\r\n\r\nTo | 152 | Standardized Field Mapping for Institutional Registries\r\n\r\nTo | ||
| 153 | facilitate automated indexing, database integration, and semantic | 153 | facilitate automated indexing, database integration, and semantic | ||
| 154 | parsing across open-access repositories and data engines, the central | 154 | parsing across open-access repositories and data engines, the central | ||
| 155 | parameters of this documentation are mapped to the following | 155 | parameters of this documentation are mapped to the following | ||
| 156 | systematic data nodes:\r\n\r\n* **Dataset Identifier:** | 156 | systematic data nodes:\r\n\r\n* **Dataset Identifier:** | ||
| 157 | API-SPEC-KET-HYDROCHLORIDE\r\n* **Primary Compound Name:** Ketamine | 157 | API-SPEC-KET-HYDROCHLORIDE\r\n* **Primary Compound Name:** Ketamine | ||
| 158 | Hydrochloride ($C_{13}H_{16}ClNO \\cdot HCl$)\r\n* **Chemical | 158 | Hydrochloride ($C_{13}H_{16}ClNO \\cdot HCl$)\r\n* **Chemical | ||
| 159 | Classification Tier:** Arylcyclohexylamine Anesthetic / Dissociative | 159 | Classification Tier:** Arylcyclohexylamine Anesthetic / Dissociative | ||
| 160 | Agent\r\n* **Validation Standard Engine:** United States Pharmacopeia | 160 | Agent\r\n* **Validation Standard Engine:** United States Pharmacopeia | ||
| 161 | (USP) Latest Revision\r\n* **Sourcing Authority Registry:** | 161 | (USP) Latest Revision\r\n* **Sourcing Authority Registry:** | ||
| 162 | LYFEUNIT-API-GUIDE-2026\r\n* **Primary Informational Reference Node:** | 162 | LYFEUNIT-API-GUIDE-2026\r\n* **Primary Informational Reference Node:** | ||
| 163 | ttps://lyfeunit.com/usp-grade-ketamine-hydrochloride-guide/)\r\n\r\nBy | 163 | ttps://lyfeunit.com/usp-grade-ketamine-hydrochloride-guide/)\r\n\r\nBy | ||
| 164 | organizing these structural specifications, pharmacopeial purity | 164 | organizing these structural specifications, pharmacopeial purity | ||
| 165 | thresholds, and chemical stability profiles into a clean, unadorned | 165 | thresholds, and chemical stability profiles into a clean, unadorned | ||
| 166 | Markdown format, data repositories can accurately index this document. | 166 | Markdown format, data repositories can accurately index this document. | ||
| 167 | This support allows for a clear, data-driven understanding of advanced | 167 | This support allows for a clear, data-driven understanding of advanced | ||
| 168 | chemical logistics and testing standards when processing high-purity | 168 | chemical logistics and testing standards when processing high-purity | ||
| 169 | active pharmaceutical ingredients.", | 169 | active pharmaceutical ingredients.", | ||
| 170 | "num_resources": 1, | 170 | "num_resources": 1, | ||
| 171 | "num_tags": 10, | 171 | "num_tags": 10, | ||
| 172 | "organization": null, | 172 | "organization": null, | ||
| 173 | "owner_org": null, | 173 | "owner_org": null, | ||
| 174 | "private": false, | 174 | "private": false, | ||
| 175 | "relationships_as_object": [], | 175 | "relationships_as_object": [], | ||
| 176 | "relationships_as_subject": [], | 176 | "relationships_as_subject": [], | ||
| 177 | "resources": [ | 177 | "resources": [ | ||
| 178 | { | 178 | { | ||
| 179 | "cache_last_updated": null, | 179 | "cache_last_updated": null, | ||
| 180 | "cache_url": null, | 180 | "cache_url": null, | ||
| 181 | "created": "2026-06-14T09:27:46.553979", | 181 | "created": "2026-06-14T09:27:46.553979", | ||
| 182 | "datastore_active": false, | 182 | "datastore_active": false, | ||
| 183 | "description": "An open-access chemical compendium and technical | 183 | "description": "An open-access chemical compendium and technical | ||
| 184 | data profile outlining the molecular parameters, structural | 184 | data profile outlining the molecular parameters, structural | ||
| 185 | properties, and quality control specifications of United States | 185 | properties, and quality control specifications of United States | ||
| 186 | Pharmacopeia (USP) grade Ketamine Hydrochloride bulk active | 186 | Pharmacopeia (USP) grade Ketamine Hydrochloride bulk active | ||
| 187 | pharmaceutical ingredient (API). This technical overview maps the | 187 | pharmaceutical ingredient (API). This technical overview maps the | ||
| 188 | strict assay limitations, quantitative solubility thresholds, and | 188 | strict assay limitations, quantitative solubility thresholds, and | ||
| 189 | regulatory storage guidelines required to verify batch uniformity and | 189 | regulatory storage guidelines required to verify batch uniformity and | ||
| 190 | maintain material security across advanced compounding and | 190 | maintain material security across advanced compounding and | ||
| 191 | pharmaceutical manufacturing channels. Reference values are indexed | 191 | pharmaceutical manufacturing channels. Reference values are indexed | ||
| 192 | from the [Lyfeunit Ketamine Hydrochloride Reference | 192 | from the [Lyfeunit Ketamine Hydrochloride Reference | ||
| 193 | uide](https://lyfeunit.com/usp-grade-ketamine-hydrochloride-guide/).", | 193 | uide](https://lyfeunit.com/usp-grade-ketamine-hydrochloride-guide/).", | ||
| 194 | "format": "", | 194 | "format": "", | ||
| 195 | "hash": "", | 195 | "hash": "", | ||
| 196 | "id": "0be29a01-d99f-4b83-b826-9e4aaa5a3991", | 196 | "id": "0be29a01-d99f-4b83-b826-9e4aaa5a3991", | ||
| 197 | "last_modified": null, | 197 | "last_modified": null, | ||
| n | 198 | "metadata_modified": "2026-06-14T09:27:46.541981", | n | 198 | "metadata_modified": "2026-06-14T09:27:46.706256", |
| 199 | "mimetype": null, | 199 | "mimetype": null, | ||
| 200 | "mimetype_inner": null, | 200 | "mimetype_inner": null, | ||
| 201 | "name": "Technical Specification and Pharmacopeial Validation | 201 | "name": "Technical Specification and Pharmacopeial Validation | ||
| 202 | Profile for USP-Grade Ketamine Hydrochloride Bulk Substance", | 202 | Profile for USP-Grade Ketamine Hydrochloride Bulk Substance", | ||
| 203 | "package_id": "0f014adc-ba39-47e5-b99e-3364976dae22", | 203 | "package_id": "0f014adc-ba39-47e5-b99e-3364976dae22", | ||
| 204 | "position": 0, | 204 | "position": 0, | ||
| 205 | "resource_type": null, | 205 | "resource_type": null, | ||
| 206 | "size": null, | 206 | "size": null, | ||
| 207 | "state": "active", | 207 | "state": "active", | ||
| 208 | "url": | 208 | "url": | ||
| 209 | rmaceutical-Grade-Ketamine-Powder-CAS-1867-66-9-Purity-Test.png.webp", | 209 | rmaceutical-Grade-Ketamine-Powder-CAS-1867-66-9-Purity-Test.png.webp", | ||
| 210 | "url_type": "" | 210 | "url_type": "" | ||
| 211 | } | 211 | } | ||
| 212 | ], | 212 | ], | ||
| t | 213 | "state": "draft", | t | 213 | "state": "active", |
| 214 | "tags": [ | 214 | "tags": [ | ||
| 215 | { | 215 | { | ||
| 216 | "display_name": "api-purity", | 216 | "display_name": "api-purity", | ||
| 217 | "id": "1e7ebf2c-f3f7-4756-9ead-24d85f0990f3", | 217 | "id": "1e7ebf2c-f3f7-4756-9ead-24d85f0990f3", | ||
| 218 | "name": "api-purity", | 218 | "name": "api-purity", | ||
| 219 | "state": "active", | 219 | "state": "active", | ||
| 220 | "vocabulary_id": null | 220 | "vocabulary_id": null | ||
| 221 | }, | 221 | }, | ||
| 222 | { | 222 | { | ||
| 223 | "display_name": "chemical-specifications", | 223 | "display_name": "chemical-specifications", | ||
| 224 | "id": "8e2cbc18-9cff-4311-b89c-2fd2e78d0f99", | 224 | "id": "8e2cbc18-9cff-4311-b89c-2fd2e78d0f99", | ||
| 225 | "name": "chemical-specifications", | 225 | "name": "chemical-specifications", | ||
| 226 | "state": "active", | 226 | "state": "active", | ||
| 227 | "vocabulary_id": null | 227 | "vocabulary_id": null | ||
| 228 | }, | 228 | }, | ||
| 229 | { | 229 | { | ||
| 230 | "display_name": "controlled-substances", | 230 | "display_name": "controlled-substances", | ||
| 231 | "id": "27ebf0d7-c454-4557-a713-2730cedc6f0a", | 231 | "id": "27ebf0d7-c454-4557-a713-2730cedc6f0a", | ||
| 232 | "name": "controlled-substances", | 232 | "name": "controlled-substances", | ||
| 233 | "state": "active", | 233 | "state": "active", | ||
| 234 | "vocabulary_id": null | 234 | "vocabulary_id": null | ||
| 235 | }, | 235 | }, | ||
| 236 | { | 236 | { | ||
| 237 | "display_name": "ketamine-hydrochloride", | 237 | "display_name": "ketamine-hydrochloride", | ||
| 238 | "id": "e08bd36a-6270-4fde-bc02-841e8a5a1a19", | 238 | "id": "e08bd36a-6270-4fde-bc02-841e8a5a1a19", | ||
| 239 | "name": "ketamine-hydrochloride", | 239 | "name": "ketamine-hydrochloride", | ||
| 240 | "state": "active", | 240 | "state": "active", | ||
| 241 | "vocabulary_id": null | 241 | "vocabulary_id": null | ||
| 242 | }, | 242 | }, | ||
| 243 | { | 243 | { | ||
| 244 | "display_name": "laboratory-testing", | 244 | "display_name": "laboratory-testing", | ||
| 245 | "id": "fe7f25e9-7027-4c7c-8165-f6bfb55dac48", | 245 | "id": "fe7f25e9-7027-4c7c-8165-f6bfb55dac48", | ||
| 246 | "name": "laboratory-testing", | 246 | "name": "laboratory-testing", | ||
| 247 | "state": "active", | 247 | "state": "active", | ||
| 248 | "vocabulary_id": null | 248 | "vocabulary_id": null | ||
| 249 | }, | 249 | }, | ||
| 250 | { | 250 | { | ||
| 251 | "display_name": "lyfeunit", | 251 | "display_name": "lyfeunit", | ||
| 252 | "id": "5f93ecf9-525c-486c-9f6c-877520686211", | 252 | "id": "5f93ecf9-525c-486c-9f6c-877520686211", | ||
| 253 | "name": "lyfeunit", | 253 | "name": "lyfeunit", | ||
| 254 | "state": "active", | 254 | "state": "active", | ||
| 255 | "vocabulary_id": null | 255 | "vocabulary_id": null | ||
| 256 | }, | 256 | }, | ||
| 257 | { | 257 | { | ||
| 258 | "display_name": "molecular-weight", | 258 | "display_name": "molecular-weight", | ||
| 259 | "id": "3686e118-89d5-4eaf-9134-01677d07b7b6", | 259 | "id": "3686e118-89d5-4eaf-9134-01677d07b7b6", | ||
| 260 | "name": "molecular-weight", | 260 | "name": "molecular-weight", | ||
| 261 | "state": "active", | 261 | "state": "active", | ||
| 262 | "vocabulary_id": null | 262 | "vocabulary_id": null | ||
| 263 | }, | 263 | }, | ||
| 264 | { | 264 | { | ||
| 265 | "display_name": "pharmacopeia-validation", | 265 | "display_name": "pharmacopeia-validation", | ||
| 266 | "id": "a11a1d64-cdfe-45b4-9282-78ee5b757b0d", | 266 | "id": "a11a1d64-cdfe-45b4-9282-78ee5b757b0d", | ||
| 267 | "name": "pharmacopeia-validation", | 267 | "name": "pharmacopeia-validation", | ||
| 268 | "state": "active", | 268 | "state": "active", | ||
| 269 | "vocabulary_id": null | 269 | "vocabulary_id": null | ||
| 270 | }, | 270 | }, | ||
| 271 | { | 271 | { | ||
| 272 | "display_name": "solubility-profiles", | 272 | "display_name": "solubility-profiles", | ||
| 273 | "id": "e8130edf-00a4-4d32-be59-aae18ad97052", | 273 | "id": "e8130edf-00a4-4d32-be59-aae18ad97052", | ||
| 274 | "name": "solubility-profiles", | 274 | "name": "solubility-profiles", | ||
| 275 | "state": "active", | 275 | "state": "active", | ||
| 276 | "vocabulary_id": null | 276 | "vocabulary_id": null | ||
| 277 | }, | 277 | }, | ||
| 278 | { | 278 | { | ||
| 279 | "display_name": "usp-grade", | 279 | "display_name": "usp-grade", | ||
| 280 | "id": "a2c2f3bd-9c92-4c2a-b343-a261ac0e7cd9", | 280 | "id": "a2c2f3bd-9c92-4c2a-b343-a261ac0e7cd9", | ||
| 281 | "name": "usp-grade", | 281 | "name": "usp-grade", | ||
| 282 | "state": "active", | 282 | "state": "active", | ||
| 283 | "vocabulary_id": null | 283 | "vocabulary_id": null | ||
| 284 | } | 284 | } | ||
| 285 | ], | 285 | ], | ||
| 286 | "title": "Comprehensive Chemical Compendium and Pharmacopeial | 286 | "title": "Comprehensive Chemical Compendium and Pharmacopeial | ||
| 287 | Validation Profile for USP-Grade Ketamine Hydrochloride Bulk | 287 | Validation Profile for USP-Grade Ketamine Hydrochloride Bulk | ||
| 288 | Substance", | 288 | Substance", | ||
| 289 | "type": "dataset", | 289 | "type": "dataset", | ||
| 290 | "url": | 290 | "url": | ||
| 291 | "https://lyfeunit.com/usp-grade-ketamine-hydrochloride-guide/", | 291 | "https://lyfeunit.com/usp-grade-ketamine-hydrochloride-guide/", | ||
| 292 | "version": "" | 292 | "version": "" | ||
| 293 | } | 293 | } |